This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Adjei, A. A. Search for Related Content PubMed PubMed Citation Articles by Adjei, A. A.

Novel Combinations Based on Epidermal Growth Factor Receptor Inhibition

Author's Affiliation: Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota

Requests for reprints: Alex A. Adjei, Division of Medical Oncology, Mayo Clinic, 200 First Street, Southwest, Rochester, MN 55905. Phone: 507-538-0548; Fax: 507-284-1803; E-mail: adjei.alex{at}mayo.edu.

In spite of recent advances in molecular biology leading to the introduction of clinically active novel agents, such as imatinib, erlotinib, and bevacizumab, therapy of the most common epithelial tumors, such as lung cancer, remains unsuccessful. The diversity of molecular abnormalities in these tumors is felt to partly contribute to their resistance to therapy. It is, therefore, widely accepted that one approach to improving the efficacy of cancer therapy is the development of rational, hypothesis-based combinations of anticancer agents that may exhibit synergistic cytotoxic interactions. A number of empirical combination studies with the epidermal growth factor receptor and classic cytotoxic agents were undertaken in clinical trials, with disappointing results. It is, therefore, felt that preclinical combinations of epidermal growth factor receptor inhibitors and other novel agents, based on sound knowledge of complementary signaling pathways whose concerted inhibition would be hypothesized to inhibit growth, is the reasonable approach in the future. A brief overview of some of these pathways (mammalian target of rapamycin, vascular endothelial growth factor receptor, and ras/mitogen-activated protein kinase signaling) is provided in this review.

This article has been cited by other articles:

				Y.-H. Ling, T. Li, Z. Yuan, M. Haigentz Jr., T. K. Weber, and R. Perez-Soler Erlotinib, an Effective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Induces p27KIP1 Up-Regulation and Nuclear Translocation in Association with Cell Growth Inhibition and G1/S Phase Arrest in Human Non-Small-Cell Lung Cancer Cell Lines Mol. Pharmacol., August 1, 2007; 72(2): 248 - 258. [Abstract] [Full Text] [PDF]

				M. V. Karamouzis, J. R. Grandis, and A. Argiris Therapies Directed Against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas JAMA, July 4, 2007; 298(1): 70 - 82. [Abstract] [Full Text] [PDF]